• 1
    Pirmohamed M, Orme M. Drug interactions of clinical importance. In: Davies's Textbook of Adverse Drug Reactions, 5th edn, eds DaviesD, FernerR, De GlanvilleH. London: Chapman & Hall Medical, 1998; 888912.
  • 2
    Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. J Drug Saf 2003; 26: 15986.
  • 3
    Alsheikh-Ali AA, Abourjaily HM, Karas RH. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). Am J Cardiol 2002; 89: 130810.
  • 4
    Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Signalling possible drug–drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol 1999; 47: 68993.
  • 5
    Van Puijenbroek EP, Egberts AC, Heerdink ER, Leufkens HG. Detecting drug–drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2000; 56: 7338.
  • 6
    DuMouchel W, Pregibon D. Empirical Bayes screening for multi-item associations. Proc KDD 2001; New York: ACM, 67–76.
  • 7
    Wu X, Barbarā D, Ye Y. Screening and interpreting multi-item associations based on log-linear modeling. Proc KDD 2003; New York: ACM, 276–85.
  • 8
    Almenoff JS, Dumouchel W, Kindman LA, Yang X, Fram D. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interaction in the post-marketing setting. Pharmacoepidemiol Drug Saf 2003; 12: 51721.
  • 9
    Norén GN, Bate A, Orre R, Edwards IR. Extending the methods used to screen the WHO drug safety database towards analysis of complex association and improved accuracy for rare events. Stat Med 2006; 25: 374057.
  • 10
    Norén GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug–drug interaction surveillance. Stat Med 2008; 27: 62712.
  • 11
    Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug–drug interactions in a spontaneous reports database. Br J Clin Pharmacol 2007; 64: 48995.
  • 12
    Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005; 4: 92948.
  • 13
    National Adverse Drug Reaction Monitoring Center. WHO Adverse Reaction Terminology. Peking: China Medicine and Technology Press, 2003.
  • 14
    Committee of Chinese Pharmacopoeia. Chinese Pharmacopoeia. Peking: Chemical Industry Press, 2005.
  • 15
    Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007; 16: 35965.
  • 16
    Du W, Levine M, Wang L, Zhang Y, Yi C, Wang H, Wang X, Xie H, Xu J, Jin H, Wang T, Huang G, Wu Y. Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai. Can J Clin Pharmacol 2007; 14: 404.
  • 17
    Ye X, Fu Z, Wang H, Du W, Wang R, Sun Y, Gao Q, He J. A computerized system for signal detection in spontaneous reporting system of Shanghai, China. Pharmacoepidemiol Drug Saf 2009; 18: 1548.
  • 18
    Egberts AC, Meyboom RH, Van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 2002; 25: 4538.
  • 19
    Skrondal A. Interaction as departure from additivity in case–control studies: a cautionary note. Am J Epidemiol 2003; 158: 2518.
  • 20
    Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol 1980; 112: 46770.
  • 21
    Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992; 3: 4526.
  • 22
    Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Eqberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting system for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 310.
  • 23
    Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO database. Drug Saf 2000; 23: 53342.
  • 24
    Li C, Xia J, Deng J, Jiang J. A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China. Pharmacoepidemiol Drug Saf 2008; 17: 593600.
  • 25
    Lin F, Wang H. Concomitant nodular goiter during IFN and ribavirin treatment of HCV: a case report. Clin J Hepatol 2006; 14: 1636.
  • 26
    Zhang J, Miao J, Zhao F, Chen S, Guo X. Analysis of effects of the combination of capecitabine and oxaliplatin as first-line chemotherapy on metastatic colorectal cancer. Mod Med J 2008; 36: 379.
  • 27
    Liang K, Li Y. Clinical observation of capecitabine combining oxaliplatin in the treatment of advanced colorectal carcinoma. Mod Oncol 2008; 16: 13656.